Company*
(Country,
Symbol)

Company*
(Country,
Symbol)

Type/Product Area

Terms/Details (Date)


Aclara Bio-
Sciences
Inc.
(ACLA)

Third Wave Technologies
Inc.
(TWTI)

Collaboration for the development and commercialization of multiplexed gene expression research products

The collaboration couples the high-multiplexing capabilities of Aclara's eTAG sequence-labeling technology with Third Wave's Invader platform (10/25)

Agilent Tech-
nologies
Inc.
(NYSE:A)

Paradigm
Genetics Inc.
(PDGM)

Multiyear collaboration to commercialize the first whole Arabidopsis thaliana genome microarray for use in gene expression studies

Paradigm will receive volume discounts on microarrays and royalties from co-developed products (10/29)

AlphaGene
Inc.*

Celera
Genomics
Group
(NYSE:CRA)

Agreement to allow Celera to distribute AlphaGene's collection of human full-length genes

Celera will be responsible for marketing these services through its Celera Discovery System subscription database; AlphaGene will be responsible for isolating known clones through its AlphaGene Clone Database, and will fully sequence and manufacture the clones (11/13)

Antisense
Therapeu-
tics Ltd.
(unit
of Circadian Technologies Ltd.; Australia)*

Isis Pharma-
ceuticals
Inc.
(ISIP)

Collaboration to discover and develop antisense drugs

Isis will be handed 14% of the issued capital of Antisense plus another 20M options (equivalent to about 23% of Antisense, if exercised) and will be entitled to royalties from drug discoveries; Antisense gains the right to commercialize ISIS 107248 (ATL 1102), a candidate for multiple sclerosis (11/21**)

Archemix
Inc.*

Gilead
Sciences
Inc.
(GILD)

Licensing agreement for Gilead's aptamer technology

Archemix will pay $17.5M for the license (10/25)

Argenta
Discovery
Ltd.
(UK)*

De Novo
Pharmaceu-
ticals Ltd.
(UK)*

Collaboration directed toward certain De Novo drug discovery targets

Argenta will provide De Novo with synthetic chemistry and screening services for the generation and testing of low-molecular- weight, drug-like compounds (10/31)

Athersys
Inc.*

3-Dimen-
sional
Pharm-
aceuticals
Inc.
(DDDP)

Collaboration to discover, develop and commercialize small-molecule drugs by screening against targets derived from the G protein-coupled receptor family of proteins

Athersys will supply the drug targets; any small-molecule drug candidates identified will be co-developed and co-commercialized on a 50-50 basis (10/29)

Atugen AG
(Germany)*

Oxford Gly-
coSciences
plc
(UK;
OGSI;LSE:
OGS)

Collaboration to validate high-priority disease-associated genetic targets of interest to OGS

OGS will provide novel high-priority drug targets to Atugen to enable validation in specific cell lines and in animal models of human diseases (12/11)

AxCell Bio-
sciences
Corp.
(a
subsidiary of
Cytogen Corp;
CYTO) and
InforMax Inc.
(INMX)

Pluvita
Corp.*

Three-year nonexclusive agreement to use AxCell's ProChart database in drug discovery; binding term sheet agreement between AxCell and Pluvita for a pilot program to research protein interactions

Financial terms were not disclosed for either agreement; the goals of the pilot program will be to identify the full-length peptides that bind Pluvita's compound, and identify apparent consensus sequences within the human proteome (12/11)

Bioject
Medical
Technologies
Inc.
(BJCT)

Amgen Inc.
(AMGN)

Agreement that broadens Amgen's potential use of Bioject's needle-free injection system and includes product licensing and commercial supply terms

Bioject will provide Amgen with an exclusive license for use of a modified version of the Bioject B2000 needle-free injection system for certain undisclosed therapeutics; Bioject will receive an up-front payment of $1M, as well as milestone and other payments (12/13)

BioSante
Pharma-
ceuticals
Inc.
(BTPH)

Corixa
Corp.
(CRXA)

Licensing agreement for BioSante's BioVant vaccine adjuvant on a nonexclusive basis

Corixa will use the adjuvant in several potential vaccines it will develop; Corixa will pay BioSante milestone payments and royalty payments on potential sales (11/8)

Bruker
Daltonics
Inc.
(BDAL)

Biacore
Interna-
tional
AB
(Sweden;
BCOR)

Agreement to attempt to integrate Biacore's surface plasmon resonance technology with Bruker's mass spectrometry capabilities

The companies expect to have products ready and begin sales sometime in 2002 (10/31)

Celera
Genomics
Group
(NYSE:CRA)

Immusol
Inc.*

Multiyear subscription agreement for the Celera Discovery System

Financial terms were not disclosed (11/8)

Celera
Genomics
Group
(NYSE:CRA)

Compaq
Canada Corp.
(Canada;
NYSE:CPQ)

Exclusive agreement in which Compaq Canada will be the preferred distributor of access to the Celera Discovery System

Compaq Canada will distribute the access to the nonprofit research community in Canada (11/7)

Cerep SA
(France;
Nouveau
Marche:CERE)

Sepracor
Inc.
(SEPR)

Five-year research and development collaboration that gives Sepracor access to Cerep's BioPrint database

Cerep will receive annual fees, as well as milestone payments and royalties (11/14**)

Cetek
Corp.*

Lexicon
Genetics
Inc.
(LEXG)

Agreement to develop assays and perform high-throughput screens against several novel in vivo validated targets

The companies will screen against targets for the discovery of lead compounds from Lexicon's compound libraries (11/12)

ChemBridge
Laborator-
ies LLC*

Tularik Inc.
(TLRK)

Two-year agreement to apply CRL's chemistry platform to Tularik's research for the discovery of novel therapeutics

CRL will receive a technology access fee and success-based milestones (12/3)

Chiron
Corp.
(CHIR)

Inhale
Therapeutic
Systems
Inc.
(INHL)

Collaboration to produce an inhaled, dry powder tobramycin therapy for the treatment of Pseudomonas aeruginosa lung infections

Inhale will develop the formulation and be responsible for clinical and commercial manufacturing; Chiron will develop the clinical protocol and commercialize the resulting product; Inhale will receive research and development funding, milestone payments and royalty payments (12/4)

Cureon A/S
(Denmark)*

Oxagen
Ltd.
(UK)*

Collaboration under which Cureon will validate a specified number of gene targets for Oxagen

Cureon will perform the work with its SmART-Validation target validation service based on locked nucleic acid technology (12/6)

Cytos Bio-
technology
AG
(Switz-
erland)*

Millennium
Pharmaceu-
ticals Inc.
(MLNM)

Agreement for two deorphaning projects in biotherapeutics to search for new disease-relevant targets and drug candidates

Millennium will acquire the rights to screen for small-molecule compounds or other drug entities directed against the targets discovered; Millennium also gains the rights to develop and commercialize protein therapeutics resulting from the collaboration; Cytos will receive an up-front payment and research milestones, and potentially commercialization milestones and license fees, as well as royalties (12/6)

DoubleTwist
Inc.*

Neurogen
Corp.
(NRGN)
& Evotec NeuroSciences GmbH (Germany)*

Subscription agreement to DoubleTwist's GenomeZone service for genomic research

The service will give the companies online access to the entire DoubleTwist Annotated Human Genome Database; financial terms were not disclosed (11/20)

Dyax Corp.
(DYAX)

Licentia Ltd.
(Finland)*

Exclusive rights agreement to develop antibody drugs and diagnostic products aimed at an undisclosed angiogenesis target

No further details were disclosed (11/27)

Epigenom-
ics
AG
(Germany)*

MethylGene
Inc.
(Canada)*

Collaboration to investigate gene methylation changes of patients enrolled in Phase II trials of MG98

MG98 is a second-generation antisense oligonucleotide that inhibits DNA methyl-transferase mRNA; financial details were not disclosed (10/30)

Epimmune
Inc.
(EPMN)

Bavarian
Nordic A/S
(Denmark;
CSE:BAVA)

Collaboration agreement to combine technologies to develop vaccines for the treatment or prevention of HIV infection

The companies will combine Epimmune's technology in the fields of T-cell epitope identification and vaccine design with Bavarian's vaccine delivery technology, Modified Vaccinia Ankara (11/29)

Eukarion
Inc.*

Proteome
Systems Inc.
(Australia)*

Collaboration on the proteomics of aging

The two companies are joining with the Buck Institute for Age Research to focus on mitochondrial oxidative stress and the role of mitochondrial dysfunction in aging and degenerative neurological disease (12/4)

ExonHit
Therapeu-
tics
SA
(France)*

Allergan
Inc.
(NYSE:
AGN)

Access agreement for ExonHit's Signal-Hit technology to identify new molecular targets for Allergan's drug discovery program

Companies will study tissue obtained from Allergan's disease model system following treatment with drug candidates; Allergan will have the option to take a commercial license for therapeutic and diagnostic rights to selected clones; Allergan will pay technology access fees, and also may make milestone and royalty payments (11/5)

Flamel Tech-
nologies
SA
(France;
FLML)

Undisclosed
biopharma-
ceutical
company

Agreement to investigate the application of Flamel's Medusa controlled-release protein and peptide delivery technology to an existing and specific class of proteins

The work will be fully funded by Flamel's partner (11/14)

Galapagos
Genomics
NV
(Belgium)*

Euroscreen
SA
(Belgium)*

Collaboration to identify activators of G protein-coupled receptors, for which no ligands are known

Galapagos will provide an arrayed collection of secreted proteins and peptides from human cells infected with the Galapagos PhenoSelect library that includes tens of thousands of human genes (12/10)

Genaco Bio-
medical
Products
Inc.*

Luminex
Corp.
(LMNX)

Multiyear agreement permitting Genaco to develop and commercialize reagent kits based on the Luminex LabMAP platform for the Chinese in vitro diagnostics market

The LabMAP platform will be marketed in China under the brand name Gena MASA (Multi-Analyte Suspension Array) (10/29)

Gene Logic
Inc.
(GLGC)

BioCarta
Inc.*

Exclusive commercial-use licensing agreement to BioCarta's collection of signal transduction pathways for use in visualizing protein interactions linked to Gene Logic's GeneExpress suite of information products

Gene Logic obtains multiyear access to BioCarta's pathways, as well as exclusive rights to use these data in the context of a commercially available database product (11/27)

GeneLink
Inc.
(OTC
BB:GNLK)

Orchid Bio-
Sciences
Inc.
(ORCH)

Commercial single nucleotide polymorphism genotyping service agreement

Orchid will perform high-throughput SNP genotyping of samples provided by GeneLink (11/15)

Gilead
Sciences
Inc.
(GILD)

OSI Pharm-
aceuticals
Inc.
(OSIP)

Agreement for Gilead to sell its oncology pipeline to OSI for up to $200M

OSI is paying $130M in cash and $40M in stock for all rights to Gilead's cancer pipeline plus the Boulder, Colo., operations; OSI will pay Gilead up to $30M more when milestones are reached in development of NX211 (11/26)

Gliatech
Inc.
(GLIA)

Abgenix Inc.
(ABGX)

Agreement for an exclusive license to develop and commercialize anti-properdin antibody therapies for all indications

The agreement is worth $40M for Gliatech; Abgenix will handle clinical development, regulatory activities, manufacturing, marketing and sales; Gliatech gets an up-front license fee of $1.5M, with the rest to come in the form of a future equity investment, potential milestone payments, and research funding for two years; it also would get royalties (11/2)

GPC Bio-
tech
AG
(Germany;
FSE:GPC)

ICOS Corp.
(ICOS)

Development and manufacturing agreement for GPC's anti-MHC class II antibodies

The agreement includes a nonexclusive license to ICOS's mammalian cell expression technology; ICOS will conduct development, scale-up and GMP manufacturing at its cell culture manufacturing facility; GPC retains all rights to develop and commercialize the product (11/26)

ICOS Corp.
(ICOS)

Afferon
Corp.*

Licensing agreement for RTX to treat urological disorders

ICOS gains worldwide rights to RTX; Afferon receives an up-front payment, milestones and royalties on any approved products; ICOS will pay for development and commercialization of RTX and any analogues (11/5)

Immune
Network
Ltd.
(Canada;
OTC BB:
IMMKF;
CDNX:IMM)

InNexus
Corp.*

Sublicense option agreement for the application of Super-Antibody technology to Immune Network's monoclonal antibodies hNM01 and 1F7

InNexus will pay Immune Network $1M in the form of common shares issued annually in three installments, in addition to a single-digit royalty (12/3)

Immuno-
medics Inc.
(IMMU)

AGEN Bio-
medical
Ltd.
(Australia)*

Licensing agreement for its method of directly labeling antibodies with technetium-99m (Tc-99m)

AGEN gains nonexclusive worldwide use with its clot-imaging agent under development (10/26)

Immusol
Inc.*

NeoGenesis
Pharmaceu-
ticals Inc.*

Collaboration to discover small-molecule drug candidates to treat HIV

NeoGenesis will apply its drug discovery technologies to Immusol's biologically validated cellular drug targets; no money is being exchanged (11/6)

Incyte
Genomics
Inc.
(INCY)
NYSE:RDY)
and subsidiary
Reddy US
Therapeutics
Inc.

Dr. Reddy's
Laboratories
Ltd.
(India;

Agreement allowing the companies access to LifeSeq Gold and ZooSeq

Financial terms were not disclosed (11/20)

Inpharm-
atica Ltd.
(UK)*

Celera Gen-
omics
Group
(NYSE:CRA)

Joint program to develop and commercialize a new version of Inpharmatica's Biopendium target and drug discovery platform

The new product is to be called Celera Edition Biopendium; it is expected to be launched early next year and will apply Inpharmatica's protein structure/function prediction technology to Celera's mammalian sequences and other public domain sequences (11/7)

Isis Pharma-
ceuticals
Inc.
(ISIP)

Amgen Inc.
(AMGN)

Three-year agreement for Isis to use its technology to discover drugs from Amgen targets

Isis will use its second-generation chemistry, 2'-0-methoxyethyl, to inhibit several gene targets; Amgen has the right to develop and commercialize any resulting antisense drugs; Isis will get an up-front fee, funding for research, milestones and royalties (12/13)

Isis Pharma-
ceuticals Inc.
(ISIP)

Chiron Corp.
(CHIR)

Target validation collaboration in which Chiron gains access to Isis' applications of antisense technology and a license to specific patents

With the property, Chiron will use the Ribonuclease H mechanism of action for its in-house antisense-based functional genomics program (12/17)

Isis Pharma-
ceuticals Inc.
(ISIP)

OncoGenex
(Canada)*

Drug development collaboration agreement to codevelop OGX-011

Isis will be responsible for conducting pre-clinical studies and will manufacture OGX-011; OncoGenex will perform Phase I/II trials of OGX-011 (11/26)

LION bio-
science AG
(Germany; LEON)

IBM Corp.
(NYSE:IBM)

Agreement to work together on harnessing the data from human genome studies so it can be used for more effective and faster drug discovery and development

IBM and LION will jointly market enterprisewide drug discovery solutions (11/28)

LION bio-
science AG
(Germany; LEON)

ACE Bio-
Sciences
A/S
(Denmark)*

Collaboration agreement in the field of proteomics

LION granted several user licenses for its software products to ACE, which will apply these modules to conduct its own proteomics research in the field of pathogenic micro-organisms (11/6)

Maxygen
Inc.
(MAXY)

Novozymes
A/S
(Denmark;
CSE:KFX)

Agreement in which Novozymes will advance into development two additional enzyme product candidates that were developed using Maxygen's Molecular-Breeding directed molecular evolution technologies

Maxygen will receive royalty payments on the sales of any products in the expanded industrial enzyme market areas; Maxygen will have co-exclusive rights to use the technologies for certain new industrial enzyme markets (11/12)

MDS
Pharma
Services
(Canada; unit
of MDS Inc.;
NYSE:MDZ;
TSE:MDS)

Iconix Pharm-
aceuticals
Inc.*

Agreement to advance a novel chemogenomics information system for drug discovery and development

MDS Pharma will help develop the system, DrugMatrix, and also will make an equity investment in Iconix, and commit other funds and technology to the development of DrugMatrix (12/12)

Medarex
Inc.
(MEDX)

Ambit Bio-
sciences
Corp.*

Multiyear collaboration to use Medarex's UltiMAb Human Antibody Development System and Ambit's ProteomeScan screening technology to develop and commercialize monoclonal antibody therapeutic products

The companies will share equally the costs and revenues of any products; Medarex made a $1M equity investment in Ambit (11/19)

Medarex
Inc.
(MEDX)

m-Phasys
GmbH
(Germany)*

Collaboration for the development and commercialization of fully human antibody therapeutics to G protein-coupled receptors

Medarex plans to generate fully human antibodies to GPCRs produced using m-Phasys' M-Fold refolding technology; the companies will jointly develop any therapeutics generated, and will share costs and commercialization rights (11/12)

Methyl-
Gene
Inc.
(Canada)*

ChemBridge
Research
Laboratories
LLC*

Research and license agreement to design small-molecule inhibitors

MethylGene gets a license to any compounds developed; CRL will get access fees, milestone payments and royalties (12/12)

Microbiotix
Inc.*

Phytobiotech
Inc.
(Canada)*

Research and screening collaboration to identify and develop antibiotic agents that inhibit bacterial DNA replication

The new antibodies will be used to address the increasing worldwide problem of antibiotic-resistant bacterial infections (10/29)

Millennium
Pharmaceu-
ticals Inc.
(MLNM)

XOMA Ltd.
(XOMA)

Agreement to further develop a pair of Millennium's biotherapeutic agents, CAB-2 and LDP-01, for certain vascular inflammation indications

XOMA is responsible for development costs through the completion of Phase II trials; it also will make initial payments to Millennium, as well as milestone payments; Millennium retains commercialization rights; it also committed to purchase at XOMA's option up to $50M worth of XOMA stock over the next three years (11/26)

Millennium
Pharmaceu-
ticals Inc.
(MLNM)

Targeted
Diagnostics
and Thera-
peutics Inc.*

Licensing agreement for TDT's intellectual property surrounding guanylyl cyclase C, and its related ST ligand, for use in colorectal cancer therapeutics

Millennium gained an exclusive worldwide license and will pay milestone fees and potential royalties to TDT; Millennium also will make an initial equity investment in TDT (12/7)

Millennium
Pharmaceu-
ticals Inc.
(MLNM)

Xenova
Group plc
(XNVA)

License agreement to develop and commercialize three of Xenova Group's potential cancer drugs

The multimillion-dollar deal aims to develop the compounds, XR11576, XR5944 and XR11612; Xenova will take the products through Phase II trials, then the companies will negotiate terms for Phase III trials; Millennium acquires development and exclusive marketing rights to the products in North America in exchange for an up-front payment of $11.5M, plus future milestones and royalties; Xenova keeps commercial rights for all products resulting from the deal outside the U.S., Canada and Mexico; Millennium will pay Xenova about $20M in research and development funding over the next two to three years (12/17)

Molecular
Mining
Corp.*

NextGen
Sciences
Ltd.
(UK)*

Agreement in the area of protein biochips

The agreement adapts the companies' respective products for optimal integration and productivity and co-promotes their products (12/5)

Myriad
Genetics Inc.
(MYGN)

Biosearch
Italia S.p.A.
(Italy; Nuovo
Mercato:BIO)

Three-year collaboration to discover therapeutic compounds using naturally occurring products

Myriad will select two or three drug targets each year from heart disease to cancer; it will develop the targets and high-throughput assays to screen against Biosearch's library (11/27)

Orchid Bio-
Sciences Inc.
(ORCH)

Invitrogen
Corp.
(IVGN)

Agreement under which Invitrogen acquired exclusive worldwide rights to offer genotyping products to the research market using Orchid's single nucleotide polymorphism scoring technology in a 96-well format

Invitrogen can develop, manufacture and market genotyping kits using Orchid's SNP scoring technology and offer customers access to Orchid's SNP primer design algorithms; Invitrogen will pay Orchid a royalty on kit sales (11/28)

Orchid Bio-
Sciences
Inc.
(ORCH)

Quest Diag-
nostics
Inc.
(NYSE:DGX)

Nonexclusive license covering the commercial use of Orchid's SNP-IT technology for gene-based diagnostic testing services using SNAPshot reagent kits marketed by Applied Biosystems Group

Orchid received an up-front payment and will earn royalties on all diagnostic services performed by Quest using Orchid technology (12/14)

Oxigene
Inc.
(OXGN)

Active
Biotech AB
(Sweden;
SSE:ACTI)

Agreement to outlicense, on a nonexclusive basis, Oxigene's benzamide technology platform for all indications

Active gains the right to further develop and commercialize positive leads for all indications; Active will bear all costs for the development and commercialization efforts and will share with Oxigene any milestone and royalty payments resulting from the program (11/26)

Paradigm
Genetics
Inc.
(PDGM)

StemCo Bio-
Medical
Inc.*

Research collaboration for the biochemical profiling of adult human stem cells

Paradigm will use its metabolomics technology platform, MetaVantage, to elucidate the biochemical profiles of adult stem cells, and will use the profiles to identify all of the small molecules present (11/19)

Paradigm
Genetics
Inc.
(PDGM)

Thermo
Electron
Corp.
(NYSE:TMO)

Strategic alliance to design and develop the next generation of chromatography/mass spectrometry systems for use in the field of metabolomics

Paradigm will provide technical and implementation consulting services to Thermo Electron's business, Thermo Finnigan, and have exclusive precommercial access to the new instruments and systems (11/6)

Plexxikon
Inc.*

Scynexis
Chemistry
& Automa-
tion
Inc.*

Agreement under which Plexxikon will access Scynexis' MedChem-Factory technology as part of a ramp-up of Plexxikon's chemistry programs

The agreement provides Plexxikon with dedicated chemistry processes using technology from chemists experienced in automation and high-throughput discovery chemistry (12/4)

Psychiatric
Genomics
Inc.*

ReNeuron
Holdings plc
(UK)*

Agreement to use fetal stem cells for growing "mini-brains" in order to screen compounds that target neurological disorders

PGI gets a worldwide exclusive license to use specific cell lines within the field of the agreement in exchange for an initial cash payment and warrants (11/30)

Prescient
Neuro-
Pharma
Inc.
(Canada;
CDNX:PRE)

Access
Oncology
Inc.*

Licensing agreement for Prescient's anticancer compound, anhydrovinblastine

The agreement could be worth more than $25M; it calls for Prescient to receive up-front payments of $1.25M, milestone payments of $17.5M, and royalties on net sales; Access will be responsible for all development and marketing costs (11/28)

Progenics
Pharmaceu-
ticals Inc.
(PGNX)

Formatech
Inc.*

Collaboration to develop improved product formulations for PRO 542

PRO 542 is in Phase II testing for HIV (10/26)

Proteome
Sciences Ltd.
(Australia)*

IBM Life
Sciences
(NYSE:IBM)

Alliance in which IBM will provide the information technology backbone for Proteome Systems' commercial offerings, including its platform for proteome analysis, ProteomIQ

The companies will collaborate on research initiatives and marketing programs; IBM will supply hardware, software and services for Proteome's in-house research and databases (11/20)

Pyro-
sequencing
AB
(Sweden;
SSE:PYRO)

Genomics
Collabora-
tive Inc.*

Partnership to accelerate the development of cardiovascular diagnostic and therapeutic products

Pyrosequencing's genotyping technology and intellectual property and GCI's clinical samples and database will be applied to the discovery and validation of genetic markers for cardiovascular disease (11/6)

Quintiles
Transna-
tional
Corp.
(QTRN)

Discovery
Laboratories
Inc.
(DSCO)

Agreement to sell and market Discovery's Surfaxin, an orphan drug being developed for respiratory distress syndrome in premature newborns

Quintiles' subsidiary, Innovex Inc., will supply Discovery with a sales force; Quintiles' investment group, PharmaBio Development Inc., will purchase $3M of Discovery common equity and make available a line of credit of $8.5M to $10M to fund premarketing activities; PharmaBio will fund the sales and marketing costs for Surfaxin for seven years; PharmaBio also may make certain milestone payments and will receive a commission on net sales over a 10-year period (12/11)

Ribozyme
Pharmaceu-
ticals Inc.
(RZYM)

Geron Corp.
(GERN)

Collaboration to accelerate the process development for Geron's lead telomerase inhibitor, GRN163

RPI will use its expertise in nucleic acid technology and will assist Geron in the scale-up and optimization of the manufacturing process; the companies also will collaborate to explore the potential for a ribozyme-based telomerase inhibitor, which Geron will have the first right to commercialize (12/6)

Rinat Neuro-
science
Corp.*

Genentech
Inc.
(NYSE:
DNA)

Licensing agreement for Genentech's genomic and bioinformatics technologies and the right to use secreted proteins, receptors and antibodies for research in the neurology field

The agreement led to Rinat's $17.5M private financing (11/6)

Rosetta Bio-
software
(unit
of Rosetta
Inc., a unit of
Inpharmatics
Merck & Co. Inc.)

COR Thera-
peutics Inc.
(CORR)

Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System

Financial terms were not disclosed (11/26)

Skye-
Pharma
plc
(UK;
SKYE;
LSE:SKP)

Astralis Ltd.
(OTC BB:
ASTR)

Agreements concerning the formulation and development of Astralis' injectable vaccine therapy, Psoraxine, to treat psoriasis

SkyePharma will receive a $5M license fee for access to DepoFoam and other relevant drug delivery technologies; SkyePharma also will provide all development, manufacturing, preclinical and clinical development services for second-generation Psoraxine, up to the completion of Phase II, and it will make an equity investment in Astralis of up to $20M (12/12)

Symyx Tech-
nologies
Inc.
(SMMX)

Celanese
Ltd.
(subsidiary
of Celanese
AG; NYSE:CZ;
Germany)

Extension to a collaboration for the discovery of catalysts for commodity chemicals

Celanese will continue to fund Symyx's discovery efforts and will have exclusive rights to commercialize materials discovered within the field of the collaboration; Symyx will receive royalties on the sale of any products commercialized (11/6)

Synt:em
(France)*

IBM Corp.
(NYSE:IBM)

Agreement in the field of virtual ultra-high-throughput screening

Synt:em will combine the IBM xSeries supercomputer cluster with its own computational predictive platform for rational drug design, Acti:map, to accelerate and optimize drug discovery (11/13)

Syrrx Inc.*

Onyx Phar-
maceuticals
Inc.
(ONXX)

Agreement in which Syrrx acquires certain assets from the small-molecule discovery program of Onyx

Syrrx will receive certain drug targets, including related reagents and assays, as well as compound libraries and licenses to certain intellectual property assets and technologies; Onyx will receive equity in Syrrx, future milestone payments and royalties on resulting products (11/6)

Third -
Wave
Tech-
nologies
Inc.
(TWTI)

Riken (The
Institute of
Physical and
Chemical
Research;
Japan)*

Worldwide exclusive licensing agreement for drug-metabolizing enzymes

The license excludes Japan; the deal involves an up-front payment to Riken and an agreement for future royalties (11/13)

Valentis
Inc.
(VLTS)

Genetronics
Biomedical
Corp.
(AMEX:
GEB)

Nonexclusive license to in vivo electroporation technology from Genetronics for use in the development of certain Genemedicine products

Financial terms were not disclosed (11/28)

Variagenics
Inc.
(VGNX)

Nanogen
Inc.
(NGEN)

Worldwide licensing agreement for patent rights to Variagenics' methylenetetrahydrofolate reductase

Variagenics granted Nanogen nonexclusive rights to commercialize home-brew and analyte-specific reagent tests aimed at the assessment of thrombo-embolic disease risk; Variagenics retains the rights to develop diagnostic tests and all other pharmacogenomic applications (11/6)

Vasogen
Inc.
(Canada;
AMEX:
MEW; TSE:
VAS)

Quest Diag-
nostics
Inc.
(NYSE:DGX)

Strategic alliance to jointly commercialize Vasogen's immune modulation therapy in the U.S.

Quest will make a US$7.5M equity investment in Vasogen; the alliance covers all indications (11/7)

Viaken
Systems
Inc.*

Sun Micro-
systems Inc.*

Agreement to introduce a new suite of data and process integration platforms

Viaken is developing a suite of discovery platforms to help eliminate discovery bottlenecks, accelerate product development, decrease R&D costs and reduce development time for life science customers (10/26)

Xerion
Pharmaceu-
ticals AG
(Germany)*

Byk

Gulden
(unit of Altana
AG; Germany)*

Target validation agreement in which Xerion will use its XCALIbur technology for analysis

Byk Gulden will provide target proteins important to diseases such as cancer and inflammation; Xerion also may provide Byk Gulden with Xcelerate technology to generate antibodies for proteins of interest (10/26)

X-Mine
Inc.*

BioCardia
Inc.*

Licensing and collaboration agreement for X-Mine's data mining and knowledge discovery platform, X-Miner

Terms involve early access to X-Mine's molecular pattern recognition and computational systems (11/3)


Notes:

# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Swedish Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange

No Comments